Date | Title | Description |
24.10.2024 | Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations | Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations
PFL-002/VERT-002 is a monoclonal antib... |
08.10.2024 | Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Met... | PFL-241/STX-241 is a highly selective, and potentially best-in-class fourth generation epidermal growth factor receptor ("EGFR") inhibitor
One of two EGFR programs being developed with Scorpion Therapeutics
CASTRES, France and BOS... |
30.08.2024 | Pierre Fabre Laboratories receives European Commission Approval for BRAFTOVI®(encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell l... | European approval is based on results from the Phase II PHAROS trial, which showed a meaningful clinical benefit to BRAFV600E mutated advanced NSCLC patients with an objective response rate (ORR) of 75% in treatment-naïve patients and 46% i... |
09.08.2024 | Eau Thermale Avène Launches Board-Certified Dermatologist Ulta Beauty Spokesperson | PARSIPPANY, N.J., Aug. 9, 2024 /PRNewswire/ -- Eau Thermale Avène, a leader in dermo-cosmetics with over 275 years of expertise rooted in dermatology and hydrotherapy, announced its partnership at Ulta Beauty with board-certified dermatolog... |
26.07.2024 | Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with MEKTOVI® (binimetinib) for the treatment of adult patients with advanced non-small cell lung ca... | The positive CHMP opinion is based on results from the Phase II PHAROS trial,[1] which demonstrated an objective response rate (ORR) of 75% in treatment-naïve patients and 46% in previously treated patients. The safety profile is consistent... |
28.06.2024 | Pierre Fabre Laboratories announce granting of European marketing authorization for OBGEMSA™ (vibegron) in overactive bladder. | CASTRES, France, June 28, 2024 /PRNewswire/ -- The European Commission (EC) has authorized the marketing of OBGEMSA™ (vibegron) by Pierre Fabre Laboratories for the symptomatic treatment of overactive bladder syndrome in adults, a particula... |
23.06.2024 | Pierre Fabre Laboratories Wins Prestigious Galien International Prize for EBVALLO® | Pierre Fabre Laboratories has been honored with the prestigious "Prix Galien International" Prize for their groundbreaking immunotherapy, EBVALLO®. This innovative treatment offers hope to patients with a rare cancer, post-transpl... |
21.06.2024 | Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer | CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indic... |
21.06.2024 | Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer | CASTRES, France, June 21, 2024 /PRNewswire/ -- Pierre Fabre Laboratories has been awarded the "Prix Galien International" Prize in the "Best Product for a Rare/Orphan Disease" category for EBVALLO® (tabelecleucel), indic... |
05.06.2024 | Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations | CASTRES, France, June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-i... |
05.06.2024 | Pierre Fabre Laboratories Announce IND Filing for PFL-002/VERT-002, a Potential Treatment for Patients with Solid Tumors, Including Non-Small Cell Lung Cancer with MET Alterations | CASTRES, France, June 5, 2024 /PRNewswire/ -- Pierre Fabre Laboratories today announced the filing of an investigational new drug ("IND") application to the U.S. Food and Drug Administration ("FDA") to initiate a first-i... |
20.05.2024 | Pierre Fabre Laboratories announces the submission by Atara Biotherapeutics of Tabelecleucel (Tab-cel®) Biologics License Application for treatment of Epstein-Barr Virus Positive Post-Transplant Lymph... | First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration
The BLA is supported by data from the pivotal Phase 3 ALLELE study which was investigating Tab-cel in relapsed or refractory EBV+ PTLD following solid organ... |
26.04.2024 | Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome | CASTRES, France , April 26, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval ... |
26.04.2024 | Pierre Fabre Laboratories receive positive CHMP opinion for OBGEMSA™(vibegron) in overactive bladder syndrome | CASTRES, France, April 26, 2024 /PRNewswire/ -- Pierre Fabre Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval o... |
01.03.2024 | Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories | Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program assets.
The transaction is in furtherance of Kinnate's previously announced ... |
23.02.2024 | Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies | 70% of rare genetic diseases start in childhood[1,2]
CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- Rare Disease Day® will be held on February 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative pr... |
15.02.2024 | Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED. | CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagemen... |
04.11.2023 | Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America | Pierre Fabre Laboratories to Acquire from Atara Biotherapeutics Commercialization Rights to EBVALLO® in the United States, Canada and All Remaining Markets
Pierre Fabre Laboratories to Take Over All Manufacturing, Clinical, and Regulatory A... |
02.11.2023 | European Medicines Agency validates Pierre Fabre Laboratories' marketing authorisation application for combination BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) for patients with BRAFV600-mutant ... | - BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) shows meaningful clinical benefit in adult patients with BRAFV600-mutant advanced NSCLC
- The application is based on results from the PHAROS study,[1] which showed an objective response ra... |
10.10.2023 | Scorpion Therapeutics and Pierre Fabre Laboratories Announce First Patient Dosed in Phase 1/2 Clinical Trial of STX-721, a Mutant-Selective EGFR Exon 20 Inhibitor for the Treatment of Locally Advanced... | -- STX-721 is characterized by high selectivity and a potentially best-in-class profile --
-- Scorpion's second program to enter clinical development this year --
-- One of two EGFR programs being developed with Pierre Fabre Laboratories --... |
25.09.2023 | Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology | CASTRES, France and CAMBRIDGE, England, Sept. 25, 2023 /PRNewswire/ -- Pierre Fabre Laboratories and Vernalis (R&D) Ltd ("Vernalis"), a fully owned subsidiary of HitGen Inc., are pleased to announce a long-term partnership to ... |
20.09.2023 | TOLREMO therapeutics Completes USD 39 Million Series A Financing Round | |
18.09.2023 | French pharma giant acquires Basel based Vertical Bio | |
12.09.2023 | Pierre Fabre Laboratories Acquires Vertical Bio and its Innovative Targeted Therapy Candidate for Patients Suffering From Non-Small Cell Lung Cancer With MET Alteration | CASTRES, France and BASEL, Switzerland, Sept. 12, 2023 /PRNewswire/ -- Pierre Fabre Laboratories, the French pharmaceutical and dermo-cosmetic company, announced the acquisition of Vertical Bio AG, a developer of novel cancer therapies. Thi... |
06.02.2023 | Pierre Fabre pursues its commitment against rare diseases in the pediatric, oncology and dermatology fields. | RARE DISEASE DAY – February 28th, 2023
The diseases are rare, but they impact a lot of people : nearly 300 million people are affected worldwide1.
CASTRES, France, Feb. 6, 2023 /PRNewswire/ -- International Rare Disease Day® will be held on... |
10.10.2022 | Pierre Fabre is taking a minority stake, via its dedicated investment subsidiary Pierre Fabre Invest, in Gennisium Pharma, an innovative company specializing in medicines for premature newborns and ni... | Gennisium finds a strategic partner with global experience and connections in the pharmaceutical industry to accelerate its development in neonatology.
Pierre Fabre strengthens its activities in the field of rare diseases, and more specific... |
15.06.2022 | Pierre Fabre and Lonza Enter Manufacturing Agreement for W0180 Antibody Drug Product | Lonza will provide clinical drug product manufacturing for W0180, an oncology drug candidate discovered by Pierre Fabre targeting solid tumors, from its fill and finish facility in Stein, Switzerland
Pierre Fabre will leverage Lonza's drug ... |
10.12.2021 | CONTROL study results show improved tolerability of NERLYNX® (neratinib) with all the investigated diarrhoea prophylaxis strategies | CASTRES, France, Dec. 10, 2021 /PRNewswire/ -- Today, the final findings of the CONTROL study1 were presented at the 2021 San Antonio Breast Cancer Symposium (SABCS). Results suggest that providing a prophylactic anti-diarrhoea medical trea... |
06.07.2021 | South-Korean biotech Y-Biologics and French mid-pharma Pierre Fabre enter into a worldwide exclusive license agreement in the highly innovative field of immuno-oncology | DAEJEON, South Korea and CASTRES, France, July 6, 2021 /PRNewswire/ -- The South Korean biotech company Y-Biologics and the French pharmaceutical group Pierre Fabre have entered into a license agreement granting worldwide exclusive rights t... |
29.06.2021 | European Organisation for Research and Treatment of Cancer (EORTC) and Pierre Fabre Partner to Address Treatment Gap for Stage 2 Melanoma Patients | Partnership builds on complementary strengths to advance research in melanoma with a focus on Stage 2 melanoma patients
BRUSSELS and CASTRES, France, June 29, 2021 /PRNewswire/ -- European Organisation for Research and Treatment of Cancer (... |
27.02.2021 | Puma Biotechnology und Pierre Fabre ändern die NERLYNX®-Lizenzvereinbarung, die neu auch Großchina einbezieht | LOS ANGELES und CASTRES (Frankreich)--(BUSINESS WIRE)--Feb 27, 2021--
Das Biopharmaunternehmen Puma Biotechnology, Inc. (Nasdaq: PBYI), und das namhafte französische Pharmaunternehmen Pierre Fabre haben eine Verlängerung der Lizenzvereinbar... |
14.12.2020 | The EspeRare Foundation and Pierre Fabre join forces to develop and market a pioneering treatment for XLHED, a dermatologic-related rare genetic disease that requires prenatal therapeutic intervention | GENEVA and CASTRES , France, Dec. 14, 2020 /PRNewswire/ -- The EspeRare Foundation and the Pierre Fabre group announced today that they have entered into a license and development collaboration agreement for the development and commercializ... |
28.11.2020 | One To Watch: Yatsen, The Chinese Cosmetics Unicorn Gone Public | Yatsen has three successful cosmetics and skincare labels under its portfolio, dubbed as one of the ... [+] pioneers to a new wave of DTC commerce in China.Perfect Diary |
- | Puma Biotechnology et Pierre Fabre amendent leur accord de licence NERLYNX® pour y inclure la Chine | LOS ANGELES, États-Unis, et CASTRES, France--(BUSINESS WIRE)--févr. 25, 2021--
Puma Biotechnology, Inc. (Nasdaq : PBYI), société biopharmaceutique, et Pierre Fabre, laboratoire pharmaceutique français de premier plan, ont convenu d’étendre ... |
- | Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China | LOS ANGELES & CASTRES, France--(BUSINESS WIRE)--Feb 25, 2021--
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 ... |